Show simple item record

dc.contributor.authorTang, Kai Dun
dc.contributor.authorBaeten, Kurt
dc.contributor.authorKenny, Liz
dc.contributor.authorFrazer, Ian H
dc.contributor.authorScheper, Gert
dc.contributor.authorPunyadeera, Chamindie
dc.date.accessioned2022-02-07T05:31:18Z
dc.date.available2022-02-07T05:31:18Z
dc.date.issued2019
dc.identifier.issn2072-6694
dc.identifier.doi10.3390/cancers11040473
dc.identifier.urihttp://hdl.handle.net/10072/412077
dc.description.abstractThe incidence of human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is rising in high-income countries, including Australia. Increasing evidence suggests that accurate HPV testing is pivotal for clinical decision making and treatment planning in these patients. Recently, the eighth edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumor-node-metastasis (TNM) staging system for OPC (based on the p16INK4a (p16) status) was proposed and has been implemented. However, the applicability of this new staging system is still far from clear. In our study, n = 127 OPC patients from Queensland, Australia were recruited, and the tumor p16 expression in these patients was examined using immunohistochemical (IHC) analysis. HPV-16 genotyping, viral load, and physical status (episomal versus integrated) in the saliva samples of OPC patients were determined using the qPCR method. A good inter-rater agreement (k = 0.612) was found between tumor p16 expression and oral HPV-16 infection in OPC. Importantly, according to the eighth edition staging system, HPV-16 DNA viral load (>10 copies/50 ng) was significantly associated with the advanced stages of OPC. In concordance with previous studies, a mixed HPV-16 form (partially or fully integrated) was predominately found in OPC patients. Taken together, our data support HPV-16 detection in saliva as a screening biomarker to identify people within the community who are at risk of developing OPC.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherMDPI
dc.relation.ispartofpagefrom473
dc.relation.ispartofissue4
dc.relation.ispartofjournalCancers
dc.relation.ispartofvolume11
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3211
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsOncology
dc.subject.keywordshuman papillomavirus
dc.subject.keywordsoropharyngeal cancer
dc.titleUnlocking the Potential of Saliva-Based Test to Detect HPV-16-Driven Oropharyngeal Cancer
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationTang, KD; Baeten, K; Kenny, L; Frazer, IH; Scheper, G; Punyadeera, C, Unlocking the Potential of Saliva-Based Test to Detect HPV-16-Driven Oropharyngeal Cancer, Cancers, 2019, 11 (4), pp. 473
dcterms.dateAccepted2019-03-26
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2022-02-07T05:29:17Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorPunyadeera, Chamindie


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record